Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 2/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.34 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | QDPR | P09417 | 3/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31700559 | 0.89 | CCNT1 (0.40) | CDK4CDK6MAP4K1WNT3ACCNT1 | |
| SCHEMBL31702486 | 0.83 | HTR2C (0.36) | CDK4CDK6MAP4K1CCNT1CDK9 | |
| SCHEMBL31700577 | 0.80 | HTR6 (0.39) | QDPRHTR6SIGMAR1 | |
| SCHEMBL31701883 | 0.77 | WNT3A (0.42) | CDK4CDK6MAP4K1WNT3ACCNT1 | |
| SCHEMBL8274827 | 0.77 | HTR2C (0.39) | CCNT1CDK9QDPRHTR6SIGMAR1 | |
| SCHEMBL31700599 | 0.75 | HTR6 (0.40) | HTR6SIGMAR1 | |
| SCHEMBL31701945 | 0.75 | HTR6 (0.40) | CDK4CDK6CCNT1CDK9QDPR | |
| SCHEMBL15168027 | 0.74 | HTR2C (0.46) | HRH3QDPRHTR6SIGMAR1 | |
| SCHEMBL31701401 | 0.73 | HRH3 (0.36) | CDK4CDK6CCNT1CDK9HRH3 | |
| SCHEMBL13977689 | 0.70 | TRPV1 (0.44) | HRH3QDPRSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250320205-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | CDK4 82/4885CDK6 162/4885MAP4K1 2321/4885 |
| US-20250320205-A1 | STAT6 DEGRADERS | STAT6, STAT1, STAT5B | CDK4 85/4885CDK6 178/4885MAP4K1 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.